Kriya cashes in $270M series C to further finance all-in-one gene therapy biznews2022-05-15T22:02:47+00:00May 15th, 2022|FierceBiotech|
mRNA Unlocked: How Technology Convergence Is Driving the Next Wavenews2022-05-13T16:39:15+00:00May 13th, 2022|FierceBiotech|
Update: Checkmate details bleak future if $250M Regeneron merger does not closenews2022-05-13T15:16:52+00:00May 13th, 2022|FierceBiotech|
Adagio still hopes to build omicron offense for lead COVID-19 therapynews2022-05-13T13:34:38+00:00May 13th, 2022|FierceBiotech|
BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS dealnews2022-05-13T12:54:12+00:00May 13th, 2022|FierceBiotech|
FDA tags Editas’ thalassemia cell therapy an orphan drug as it rounds final bend in race to clinicnews2022-05-13T11:29:35+00:00May 13th, 2022|FierceBiotech|
Roche’s TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drugnews2022-05-13T08:55:05+00:00May 13th, 2022|FierceBiotech|
Chutes & Ladders—Moderna CFO Gomez departs after just one day following unearthed investigationnews2022-05-12T17:24:57+00:00May 12th, 2022|FierceBiotech|
Bristol Myers provides Bridge over troubled water with $905M deal to enter SHP2 racenews2022-05-12T12:58:21+00:00May 12th, 2022|FierceBiotech|
After 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhomnews2022-05-12T11:47:42+00:00May 12th, 2022|FierceBiotech|
